REFIXIA (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
REFIXIA
Date registered
Evaluation commenced
Decision date
Approval time
97 (120 working days)
Active ingredients
nonacog beta pegol
Registration type
EOI
Indication
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Refixia can be used for all age groups.